IMVT forecasts a Q4 EPS of -$0.63 and $0M revenue, with recent upward revisions to earnings estimates.
Immunovant (IMVT) will report Q4 2026 earnings on May 20 before the market opens. Analysts expect a loss of $0.63 per share, improving 1.6% year-over-year, and revenue of $0M.
Over the last three months, EPS estimates have seen one upward revision with no downward adjustments. The company has not provided additional guidance beyond consensus estimates.
No immediate market reaction details were disclosed ahead of the announcement.